Rosetta Genomics Ltd (ROSG) 1.07 $ROSG
Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment
BusinessWire - Mon Jul 11, 7:59AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent Application No. 14/505,548, entitled "Compositions and methods for treatment of Ovarian Cancer," which covers a method of treatment for ovarian cancer through the administration of an inhibitor of miR-27a.
ROSG: 1.07 (unch), MIRN: 4.42 (+0.06)
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
BusinessWire - Thu Jun 23, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Stratose Inc., as a preferred laboratory provider.
ROSG: 1.07 (unch)
Rosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay
BusinessWire - Thu May 26, 6:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company's novel, microRNA-based assay for the classification of indeterminate thyroid nodules have been published online in the peer-reviewed journal, Cancer Cytopathology. The article, "Analytical Validity of a microRNA-based Assay for Diagnosing Indeterminate Thyroid FNA Smears from Routinely Prepared Cytology Slides," highlights the robustness of RosettaGX Reveal(TM), a test that stratifies indeterminate thyroid lesions as "benign," "suspicious for malignancy by microRNA" or "positive for medullary carcinoma" in preoperative Fine Needle Aspirate (FNA) by utilizing existing cytology smear samples. The article can be accessed here.
ROSG: 1.07 (unch)
Rosetta Genomics Receives Approval from New York State for Four PCR-Based Assays
BusinessWire - Mon May 23, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health (NYSDOH) for the Company's allele-specific PCR (CAST PCR)-based assays to test for BRAF, EGFR, KRAS and NRAS mutations in lung, colon and melanoma cancers. NYSDOH approval was granted under the Company's Molecular Oncology and Cellular Tumor Marker permit.
ROSG: 1.07 (unch)
Rosetta Genomics Reports 2016 First Quarter Financial Results
BusinessWire - Thu May 19, 7:00AM CDT
--Conference call begins today at 10:00 a.m. Eastern time
ROSG: 1.07 (unch)
Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016
BusinessWire - Mon May 16, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31, 2016 on Form 6K with the U.S. Securities and Exchange Commission ("SEC"
before the opening of the U.S. financial markets on May, 19, 2016. The Form 6K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6K will be available at www.sec.gov and at www.rosettagenomics.com.
ROSG: 1.07 (unch)
Rosetta Genomics Reports 2015 Full Year Financial Results
BusinessWire - Wed Mar 23, 3:05PM CDT
--Conference call begins today at 5:00 p.m. Eastern time
ROSG: 1.07 (unch)
Rosetta Genomics to Host Business Update and 2015 Year-End Financial Results Conference Call on March 23, 2016
BusinessWire - Thu Mar 17, 7:30AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.S. stock market on Wednesday, March 23, 2016, the Company will file its financial results for the 12 months ended December 31, 2015 on Form 20-F with the U.S. Securities and Exchange Commission ("SEC" . The Form 20-F will include audited consolidated financial statements, as well as additional information regarding the Company. The Form 20-F will be available at www.sec.gov and at www.rosettagenomics.com.
ROSG: 1.07 (unch)
Rosetta Genomics Announces Agreement with America's Choice Provider Network for Entire Suite of Diagnostic Tests and Services
BusinessWire - Mon Feb 01, 7:00AM CST
--Includes RosettaGX Reveal(TM) for classification of indeterminate thyroid nodules, increasing the covered lives for this first-of-its kind assay to over 150 million
ROSG: 1.07 (unch)
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for Classification of Kidney Tumors
BusinessWire - Mon Jan 25, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 14/168,981, relating to "Gene Expression Signature for Classification of Kidney Tumors." The allowed patent claims a method for distinguishing four different types of kidney cancer: oncocytoma, clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC in a human subject with renal cancer, through the expression profile of 29 microRNAs, and particularly hsa-miR-139-5p, detected by real time polymerase chain reaction (RT-PCR).
ROSG: 1.07 (unch)
CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 9:19AM CST
Headline of release should read: Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer (instead of Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer). In addition, there is a change to the first paragraph, first sentence. "U.S. Patent" should read "European Patent."
ROSG: 1.07 (unch), RGLS: 3.72 (+0.15)
Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 8:11AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 08844596.0, relating to "Targeting microRNAs for the Treatment of Liver Cancer." This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq:RGLS). The patent claims chemically-modified, anti-microRNA molecules for use in the treatment of liver cancer, including miR-21, miR-125a, miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.
ROSG: 1.07 (unch), RGLS: 3.72 (+0.15)
Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the Development of Oncology Therapeutics
BusinessWire - Wed Jan 06, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the signing of an agreement with Mirna Therapeutics (NASDAQ: MIRN), for a worldwide sublicense to Rosetta's patents related to therapeutic uses of certain microRNA technologies. The agreement includes an exclusive sublicense related to Mirna's MRX34 product candidate, a mimic of naturally occurring microRNA-34 being evaluated in clinical studies for a variety of cancers.
ROSG: 1.07 (unch), MIRN: 4.42 (+0.06)
BUYINS.NET: PTH, GOODO, ROSG, FXH, USL, MGC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Dec 22, 6:42AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PowerShares Dynamic Heathcare Sector Portfolio (NYSE
TH), Gladstone Commercial Corp (NASDAQ:GOODO), Rosetta Genomics Ltd (NASDAQ:ROSG), First Trust Health Care AlphaDEX Fund (NYSE:FXH), United States 12 Month Oil Fund LP (NYSE:USL), Midasco Capital Corp (NYSE:MGC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ROSG: 1.07 (unch), MGC: 73.92 (-0.17), PTH: 49.00 (+0.04), GOOD: 17.96 (-0.24), FXH: 61.44 (-0.10), GOODO: 25.38 (-0.13), USL: 16.38 (-0.53)
4 Stocks Under $10 Showing Great Upside Today
ACCESSWIRE - Fri Dec 18, 9:47AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
FREE: 1.15 (-0.52), OCAT: 8.47 (+0.01), ROSG: 1.07 (unch), BIOD: 0.41 (-0.03)
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis
BusinessWire - Mon Dec 14, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc. (NASDAQ:BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announce the successful completion of feasibility studies under a previously announced collaboration to evaluate the use of Biocept's patented microfluidic channel technology to extract circulating tumor cells (CTCs) from blood and Rosetta Genomics' technical expertise and proprietary qRT-PCR platform to characterize microRNAs isolated from those CTCs.
ROSG: 1.07 (unch), BIOC: 0.68 (+0.03)
Rosetta Genomics to Present at the LD Micro Main Event
ACCESSWIRE - Tue Nov 24, 7:31AM CST
PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / November 24, 2015 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that it will be presenting at the 8th annual LD Micro Main Event on Wednesday, December 2nd at 8:30 a.m. PST/11:30 a.m. EST. Kenneth A. Berlin, Rosetta's President and Chief Executive Officer, will be giving the presentation and meeting with investors.
ROSG: 1.07 (unch)
Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal(TM) (Thyroid microRNA Classifier)
BusinessWire - Thu Nov 12, 7:58AM CST
--Beginning to Receive and Process Commercial Samples
ROSG: 1.07 (unch)
Rosetta Genomics Appoints Dr. Maria Fe Paz as Interim Chief Medical Officer
BusinessWire - Wed Nov 04, 7:30AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Maria Fe Paz, M.D. Ph.D., effective immediately, as a medical affairs consultant in the role of Interim Chief Medical Officer, with plans to transition her to Chief Medical Officer of Rosetta Genomics upon receipt of a valid work visa that supports her planned relocation to the U.S.
ROSG: 1.07 (unch)
Rosetta Genomics Reports Financial Results for the First Half of 2015
BusinessWire - Mon Oct 26, 4:20PM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the six months ended June 30, 2015.
ROSG: 1.07 (unch)
Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment
BusinessWire - Mon Jul 11, 7:59AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent Application No. 14/505,548, entitled "Compositions and methods for treatment of Ovarian Cancer," which covers a method of treatment for ovarian cancer through the administration of an inhibitor of miR-27a.
ROSG: 1.07 (unch), MIRN: 4.42 (+0.06)
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
BusinessWire - Thu Jun 23, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Stratose Inc., as a preferred laboratory provider.
ROSG: 1.07 (unch)
Rosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay
BusinessWire - Thu May 26, 6:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company's novel, microRNA-based assay for the classification of indeterminate thyroid nodules have been published online in the peer-reviewed journal, Cancer Cytopathology. The article, "Analytical Validity of a microRNA-based Assay for Diagnosing Indeterminate Thyroid FNA Smears from Routinely Prepared Cytology Slides," highlights the robustness of RosettaGX Reveal(TM), a test that stratifies indeterminate thyroid lesions as "benign," "suspicious for malignancy by microRNA" or "positive for medullary carcinoma" in preoperative Fine Needle Aspirate (FNA) by utilizing existing cytology smear samples. The article can be accessed here.
ROSG: 1.07 (unch)
Rosetta Genomics Receives Approval from New York State for Four PCR-Based Assays
BusinessWire - Mon May 23, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health (NYSDOH) for the Company's allele-specific PCR (CAST PCR)-based assays to test for BRAF, EGFR, KRAS and NRAS mutations in lung, colon and melanoma cancers. NYSDOH approval was granted under the Company's Molecular Oncology and Cellular Tumor Marker permit.
ROSG: 1.07 (unch)
Rosetta Genomics Reports 2016 First Quarter Financial Results
BusinessWire - Thu May 19, 7:00AM CDT
--Conference call begins today at 10:00 a.m. Eastern time
ROSG: 1.07 (unch)
Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016
BusinessWire - Mon May 16, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31, 2016 on Form 6K with the U.S. Securities and Exchange Commission ("SEC"
before the opening of the U.S. financial markets on May, 19, 2016. The Form 6K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6K will be available at www.sec.gov and at www.rosettagenomics.com. ROSG: 1.07 (unch)
Rosetta Genomics Reports 2015 Full Year Financial Results
BusinessWire - Wed Mar 23, 3:05PM CDT
--Conference call begins today at 5:00 p.m. Eastern time
ROSG: 1.07 (unch)
Rosetta Genomics to Host Business Update and 2015 Year-End Financial Results Conference Call on March 23, 2016
BusinessWire - Thu Mar 17, 7:30AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.S. stock market on Wednesday, March 23, 2016, the Company will file its financial results for the 12 months ended December 31, 2015 on Form 20-F with the U.S. Securities and Exchange Commission ("SEC"
. The Form 20-F will include audited consolidated financial statements, as well as additional information regarding the Company. The Form 20-F will be available at www.sec.gov and at www.rosettagenomics.com. ROSG: 1.07 (unch)
Rosetta Genomics Announces Agreement with America's Choice Provider Network for Entire Suite of Diagnostic Tests and Services
BusinessWire - Mon Feb 01, 7:00AM CST
--Includes RosettaGX Reveal(TM) for classification of indeterminate thyroid nodules, increasing the covered lives for this first-of-its kind assay to over 150 million
ROSG: 1.07 (unch)
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for Classification of Kidney Tumors
BusinessWire - Mon Jan 25, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 14/168,981, relating to "Gene Expression Signature for Classification of Kidney Tumors." The allowed patent claims a method for distinguishing four different types of kidney cancer: oncocytoma, clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC in a human subject with renal cancer, through the expression profile of 29 microRNAs, and particularly hsa-miR-139-5p, detected by real time polymerase chain reaction (RT-PCR).
ROSG: 1.07 (unch)
CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 9:19AM CST
Headline of release should read: Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer (instead of Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer). In addition, there is a change to the first paragraph, first sentence. "U.S. Patent" should read "European Patent."
ROSG: 1.07 (unch), RGLS: 3.72 (+0.15)
Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 8:11AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 08844596.0, relating to "Targeting microRNAs for the Treatment of Liver Cancer." This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq:RGLS). The patent claims chemically-modified, anti-microRNA molecules for use in the treatment of liver cancer, including miR-21, miR-125a, miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.
ROSG: 1.07 (unch), RGLS: 3.72 (+0.15)
Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the Development of Oncology Therapeutics
BusinessWire - Wed Jan 06, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the signing of an agreement with Mirna Therapeutics (NASDAQ: MIRN), for a worldwide sublicense to Rosetta's patents related to therapeutic uses of certain microRNA technologies. The agreement includes an exclusive sublicense related to Mirna's MRX34 product candidate, a mimic of naturally occurring microRNA-34 being evaluated in clinical studies for a variety of cancers.
ROSG: 1.07 (unch), MIRN: 4.42 (+0.06)
BUYINS.NET: PTH, GOODO, ROSG, FXH, USL, MGC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Dec 22, 6:42AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PowerShares Dynamic Heathcare Sector Portfolio (NYSE
TH), Gladstone Commercial Corp (NASDAQ:GOODO), Rosetta Genomics Ltd (NASDAQ:ROSG), First Trust Health Care AlphaDEX Fund (NYSE:FXH), United States 12 Month Oil Fund LP (NYSE:USL), Midasco Capital Corp (NYSE:MGC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: ROSG: 1.07 (unch), MGC: 73.92 (-0.17), PTH: 49.00 (+0.04), GOOD: 17.96 (-0.24), FXH: 61.44 (-0.10), GOODO: 25.38 (-0.13), USL: 16.38 (-0.53)
4 Stocks Under $10 Showing Great Upside Today
ACCESSWIRE - Fri Dec 18, 9:47AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
FREE: 1.15 (-0.52), OCAT: 8.47 (+0.01), ROSG: 1.07 (unch), BIOD: 0.41 (-0.03)
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis
BusinessWire - Mon Dec 14, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc. (NASDAQ:BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announce the successful completion of feasibility studies under a previously announced collaboration to evaluate the use of Biocept's patented microfluidic channel technology to extract circulating tumor cells (CTCs) from blood and Rosetta Genomics' technical expertise and proprietary qRT-PCR platform to characterize microRNAs isolated from those CTCs.
ROSG: 1.07 (unch), BIOC: 0.68 (+0.03)
Rosetta Genomics to Present at the LD Micro Main Event
ACCESSWIRE - Tue Nov 24, 7:31AM CST
PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / November 24, 2015 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that it will be presenting at the 8th annual LD Micro Main Event on Wednesday, December 2nd at 8:30 a.m. PST/11:30 a.m. EST. Kenneth A. Berlin, Rosetta's President and Chief Executive Officer, will be giving the presentation and meeting with investors.
ROSG: 1.07 (unch)
Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal(TM) (Thyroid microRNA Classifier)
BusinessWire - Thu Nov 12, 7:58AM CST
--Beginning to Receive and Process Commercial Samples
ROSG: 1.07 (unch)
Rosetta Genomics Appoints Dr. Maria Fe Paz as Interim Chief Medical Officer
BusinessWire - Wed Nov 04, 7:30AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Maria Fe Paz, M.D. Ph.D., effective immediately, as a medical affairs consultant in the role of Interim Chief Medical Officer, with plans to transition her to Chief Medical Officer of Rosetta Genomics upon receipt of a valid work visa that supports her planned relocation to the U.S.
ROSG: 1.07 (unch)
Rosetta Genomics Reports Financial Results for the First Half of 2015
BusinessWire - Mon Oct 26, 4:20PM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the six months ended June 30, 2015.
ROSG: 1.07 (unch)
